Drug Trial Radar · NCT01442038
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Last checked: Nov 20, 2026Latest source record: Jul 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,651
Actual
Start
Oct 2011
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Sep 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.
Conditions
- Coronary Artery Disease
- Angina Pectoris
Interventions
RanolazineDrug
Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
PlaceboDrug
Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without RevascularizationTime frame: Baseline through end of study (average 90 weeks)
Locations
218 sites in 15 countries. Site status is shown where the registry gives one.
Cardiology, PC
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Heart Center Research, LLC
Huntsville, Alabama
Scottsdale Healthcare
Scottsdale, Arizona
Scottsdale Healthcare
Scottsdale, Arizona
University of California San Diego
La Jolla, California
Spectrum Clinical Research Institute, Inc
Moreno Valley, California
Veterans Affairs San Diego Healthcare System
San Diego, California
John Muir Medical Center Concord Campus
Walnut Creek, California
South Denver Cardiology Associates, PC
Littleton, Colorado
Yale University School of Medicine
New Haven, Connecticut
Cardiology Associates of Fairfield County, PC
Stamford, Connecticut
Washington Hospital Center
Washington D.C., District of Columbia
Zasa Clinical Research
Atlantis, Florida
Cardiology Research Associates
Daytona Beach, Florida
Broward General Medical Center
Fort Lauderdale, Florida
University of Florida
Gainesville, Florida
Michigan Heart, PC
Hialeah, Florida
Jacksonville Heart Center
Jacksonville, Florida
University of Florida Health Sciences Center-Jacksonville
Jacksonville, Florida
East Coast Institute for Research
Jacksonville, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Florida Heart Institute
Orlando, Florida
Cardiovascular Institute of Northwest Florida
Panama City, Florida
Tallahassee Research Institute
Tallahassee, Florida
Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute
Tampa, Florida
University of Chicago Medical Center
Chicago, Illinois
Gateway Cardiology, PC
Jerseyville, Illinois
Indiana Heart Physicians, Inc.
Indianapolis, Indiana
The Indiana Heart Hospital
Indianapolis, Indiana
Northwest Indiana Cardiovascular Physicians
Valparaiso, Indiana
Iowa Heart Center
West de Moines, Iowa
Saint Joseph Cardiology Associates
Lexington, Kentucky
Clinical Trials of America, Inc.
Minden, Louisiana
Clinical Trials of America, Inc.
Shreveport, Louisiana
Northeast Cardiology Associates
Bangor, Maine
Baltimore Heart Associates
Baltimore, Maryland
Union Memorial Hospital
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Showing 40 of 218 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.